Evidence receipt
PIONEER 1: what the trial found
A plain-language summary of one study: who took part, what they got, what it was compared with, what happened in each group, its limits and who paid for it. One trial. Results are group averages, not a prediction for any one person.
Study: PIONEER 1[1]
Does daily oral semaglutide lower blood sugar compared with placebo in early type 2 diabetes?
- Who was in it
- 703 adults with type 2 diabetes managed with diet and exercise alone
- What they got
- Oral semaglutide 3, 7 or 14 mg once a day
- Compared with
- Placebo
- How long
- 26 weeks
- What happened
- HbA1c, compared with placebo: −0.6, −0.9 and −1.1 percentage points (3, 7, 14 mg). Weight, compared with placebo: −0.1, −0.9 and −2.3 kg.
- Limits
- 26 weeks
- Early diabetes only, no active comparator
- Strict fasting dosing rules may differ from daily life
- Funded by
- Novo Nordisk
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Sources
- PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care, September 2019. https://pubmed.ncbi.nlm.nih.gov/31186300/ · DOI 10.2337/dc19-0749 · PMID 31186300. Accessed November 2, 2026. Back to the text
Discussed in: Oral semaglutide (Rybelsus, Wegovy pill), explained
General information, not medical advice.